Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort.

ABSTRACT:

SUBMITTER: Miao Y 

PROVIDER: S-EPMC10412547 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature